Q3 2025 Earnings Call Transcript November 4, 2025 Verastem, Inc. misses on earnings expectations. Reported EPS is $-1.35 EPS, ...

A live webcast of the fireside chats can be accessed under “Events & Presentations” in the Investor section of the Company’s website, https://investor.verastem.com/events. A replay of the webcasts ...

New research from Moffitt Cancer Center shows that RAS(ON) multi-selective inhibition can directly block tumor growth and ...

New case studies on first-line pancreatic cancer patients treated with atebimetinib in combination with FOLFIRINOX to be shared by trial ...

The company expects to share safety and efficacy results from the RAMP-205 expansion cohort in first-line advanced pancreatic cancer and initial results from the Phase I/IIa trial evaluating VS-7375 ...

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

An announcement from Pasithea Therapeutics Corp ( ($KTTA) ) is now available. On November 4, 2025, Pasithea Therapeutics Corp announced the ...

Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, today announced ...

BackgroundSepsis is a complex clinical syndrome characterized by dysregulated immune responses, systemic inflammation, and multi-organ dysfunction. It ...

The research conducted by Professor Zou Zui and his team focuses on the immunoregulatory mechanisms in sepsis. As a ...

Peptides derived from endogenous regulatory proteins are believed to often serve as intriguing molecular probes in neuroscience and related fields.